Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002

D. J. Farrell, J. Pluim, R. B. Nieman (London, United Kingdom; Bridgewater, United States Of America)

Source: Annual Congress 2004 - Exotic respiratory infections
Session: Exotic respiratory infections
Session type: Thematic Poster Session
Number: 3902
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. J. Farrell, J. Pluim, R. B. Nieman (London, United Kingdom; Bridgewater, United States Of America). Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002. Eur Respir J 2004; 24: Suppl. 48, 3902

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004)
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002
Source: Eur Respir J 2004; 24: Suppl. 48, 186s
Year: 2004

Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004)
Source: Eur Respir J 2006; 28: Suppl. 50, 350s
Year: 2006

Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 566s
Year: 2003

Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001

Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors
Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD
Year: 2003


Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 351s
Year: 2003

Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 544s
Year: 2002

Antibiotic treatment and prevention of exacerbations of COPD
Source: Eur Respir Monogr 2013; 60: 96-106
Year: 2013


Clinical evaluation of patients with acute exacerbation of chronic bronchitis treated emperically with telithromycin
Source: Eur Respir J 2004; 24: Suppl. 48, 638s
Year: 2004

Antimicrobial profile and bacterial resistance in patients wit acute exacerbation of COPD, an Upper Egypt multicenters experience
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013

Correlation between sputum colour and isolation of an infecting organism in patients with acute exacerbations of chronic bronchitis (AECB)
Source: Annual Congress 2007 - Aetiology, mechanisms and treatment in lower respiratory tract infections
Year: 2007


Impact of telithromycin (T), azithromycin (A) and cefuroxime axetil (C) on the carriage of resistant streptococcus pneumoniae (Sp) in pts with acute exacerbation of chronic bronchitis (AECB)
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007


Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results
Source: Eur Respir J 2012; 40: 17-27
Year: 2012



Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD)
Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Year: 2009


Correlation between eradication of infecting organism on days 3-5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB)
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007


Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015



New clinical perspectives in AECB
Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI
Year: 2005

Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD
Source: Eur Respir J 2009; 34: 1066-1071
Year: 2009



Antibiotics and new guidelines for the treatment of lower respiratory tract infections
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=175
Year: 2004